280 related articles for article (PubMed ID: 30170560)
1. The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review.
Yamauchi R; Araki T; Mitsuyama K; Tokito T; Ishii H; Yoshioka S; Kuwaki K; Mori A; Yoshimura T; Tsuruta O; Torimura T
BMC Gastroenterol; 2018 Aug; 18(1):135. PubMed ID: 30170560
[TBL] [Abstract][Full Text] [Related]
2. A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine.
Kikuchi H; Sakuraba H; Akemoto Y; Murai Y; Fukutoku Y; Asari T; Tatsuta T; Hasui K; Hiraga H; Sawaya M; Chinda D; Mikami T; Tanaka M; Fukuda S
Immunol Med; 2019 Mar; 42(1):39-44. PubMed ID: 30917094
[TBL] [Abstract][Full Text] [Related]
3. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
Obara K; Masuzawa M; Amoh Y
J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike-report of new cases and review of the literature.
Cañete F; Mañosa M; Lobatón T; Mesonero F; Rodríguez-Lago I; Cabré E; Cabriada JL; López-Sanromán A; Domènech E
Int J Colorectal Dis; 2019 May; 34(5):861-865. PubMed ID: 30826963
[TBL] [Abstract][Full Text] [Related]
5. Managing immune checkpoint-blocking antibody side effects.
Postow MA
Am Soc Clin Oncol Educ Book; 2015; ():76-83. PubMed ID: 25993145
[TBL] [Abstract][Full Text] [Related]
6. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
7. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
8. Remission of ulcerative colitis flare-up induced by nivolumab.
Iwamoto M; Kato K; Moriyama M; Yamaguchi K; Takahashi S
Int J Colorectal Dis; 2020 Sep; 35(9):1791-1795. PubMed ID: 32458394
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
10. [Ulcerative colitis and thrombocytopenia: a clinical case of fortuitous association?].
Braucci S; Trappolini F; Angrisani L; Luberti E; Clarice A; Proietta M; Pisani D; Trappolini M
Clin Ter; 2007; 158(1):27-30. PubMed ID: 17405657
[TBL] [Abstract][Full Text] [Related]
11. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint Inhibitor-Induced Colitis.
Bellaguarda E; Hanauer S
Am J Gastroenterol; 2020 Feb; 115(2):202-210. PubMed ID: 31922959
[TBL] [Abstract][Full Text] [Related]
13. [Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition].
Oppel-Heuchel H; Grimm MO
Urologe A; 2016 May; 55(5):677-90. PubMed ID: 27146870
[TBL] [Abstract][Full Text] [Related]
14. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
16. New Onset Bloody Diarrhea in a Liver Transplant Recipient. New Onset Bloody Diarrhea in a Liver Transplant Recipient.
Mellinger JL; Pletneva M; Fontana RJ
Gastroenterology; 2015 Aug; 149(2):300-1. PubMed ID: 26086548
[No Abstract] [Full Text] [Related]
17. Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.
Kao JC; Liao B; Markovic SN; Klein CJ; Naddaf E; Staff NP; Liewluck T; Hammack JE; Sandroni P; Finnes H; Mauermann ML
JAMA Neurol; 2017 Oct; 74(10):1216-1222. PubMed ID: 28873125
[TBL] [Abstract][Full Text] [Related]
18. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient.
Kanno H; Ishida K; Yamada W; Nishida T; Takahashi N; Mochizuki K; Mizuno Y; Matsuyama K; Takahashi T; Seishima M
J Infect Chemother; 2017 Nov; 23(11):774-777. PubMed ID: 28527652
[TBL] [Abstract][Full Text] [Related]
19. [A case of severe colitis caused by immune checkpoint inhibitor].
Kanamori H; Yasuhara H; Mashima S; Suto K; Yamauchi K; Akita M; Jinno H; Hata H; Nakatsu M; Ando M
Nihon Shokakibyo Gakkai Zasshi; 2019; 116(3):235-240. PubMed ID: 30853676
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies.
Collins M; Michot JM; Danlos FX; Mussini C; Soularue E; Mateus C; Loirat D; Buisson A; Rosa I; Lambotte O; Laghouati S; Chaput N; Coutzac C; Voisin AL; Soria JC; Marabelle A; Champiat S; Robert C; Carbonnel F
Ann Oncol; 2017 Nov; 28(11):2860-2865. PubMed ID: 29045560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
